让患者参与有关取消处方的对话

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Review of Clinical Pharmacology Pub Date : 2024-04-15 DOI:10.1080/17512433.2024.2343913

Barbara Farrell

引用次数: 0

摘要

发表于《临床药理学专家评论》（刚刚接受，2024 年）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Engaging patients in conversations about deprescribing

Published in Expert Review of Clinical Pharmacology (Just accepted, 2024)

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Review of Clinical Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

7.30

自引率

2.30%

发文量

127

期刊介绍： Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.